A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Chemico-Biological Interactions

• Publication date

  2002-11-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0009-2797(02)00051-0PMID 12399152
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acetylsalicylic acid—inducer of cytochrome P-450 2E1?

  2007cited by this paper
• Increased urinary excretion of toxic hydrazino metabolites of isoniazid by slow acetylators. Effect of a slow-release preparation of isoniazid

  2004cited by this paper
• Clinical Significance of Pharmacokinetic Interactions Between Antiepileptic and Psychotropic Drugs

  2002cited by this paper
• Human CYP3A4 and the metabolism of nefazodone and hydroxynefazodone by human liver microsomes and heterologously expressed enzymes.

  2002cited by this paper
• CYP2E1-mediated modulation of valproic acid-induced hepatocytotoxicity.

  2001cited by this paper
• Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission.

  2001cited by this paper
• Flutamide-induced hepatotoxicity: report of a case series.

  2001cited by this paper
• Possible Interaction of Zopiclone and Nefazodone

  2001cited by this paper
• Antiepileptic Hypersensitivity Syndrome in Children

  2001cited by this paper
• Toxic interaction of didanosine and acetaminophen leading to severe hepatitis and pancreatitis: a case report and review of the literature

  2001cited by this paper
• Inhibition of proliferation of HT-29 colon adenocarcinoma cells by carboxylate NSAIDs and their acyl glucuronides.

  2001cited by this paper
• Toxic interaction of didanosine and acetaminophen leading to severe hepatitis and pancreatitis: a case report and review of the literature.

  2001cited by this paper
• Hepatic failure and encephalopathy attributed to an interaction between acetaminophen and rifampicin

  2001cited by this paper
• Idiosyncratic drug allergic phenprocoumon-induced hepatitis with subacute liver failure initially misdiagnosed as autoimmune hepatitis.

  2001cited by this paper
• Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide

  2001cited by this paper
• Hepatotoxicity With Antiretroviral Treatment of Pregnant Women

  2001cited by this paper
• Acute Hepatitis Induced by Cyproterone Acetate

  2001cited by this paper
• Drug interaction: Omeprazole and Phenprocoumon

  2001cited by this paper
• Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects

  2001cited by this paper
• Ecstasy ingestion and fulminant hepatic failure: liver transplantation to be considered as a last therapeutic option.

  2001cited by this paper
• Serotonergic neurotoxicity of 3,4-(+/-)-methylenedioxyamphetamine and 3,4-(+/-)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase.

  2001cited by this paper
• Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation.

  2000cited by this paper
• CASE REPORT: Troglitazone-Induced Fulminant Hepatic Failure

  2000cited by this paper
• Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group.

  2000cited by this paper
• Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination.

  2000cited by this paper
• A case of pharmacokinetic interference in comedication of clozapine and valproic acid.

  2000cited by this paper
• Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation

  2000cited by this paper
• Target proteins in human autoimmunity: cytochromes P450 and UDP- glucuronosyltransferases.

  2000cited by this paper
• Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies

  2000cited by this paper
• Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate.

  1999cited by this paper
• Sex-specific induction of apoptosis by cyproterone acetate in primary rat hepatocytes.

  1999cited by this paper
• N‐tert‐butyl‐alpha‐phenylnitrone protects against 3,4‐methylenedioxymethamphetamine‐induced depletion of serotonin in rats

  1999cited by this paper
• Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group.

  1999cited by this paper
• Opposite behaviors of reactive metabolites of tienilic acid and its isomer toward liver proteins: use of specific anti-tienilic acid-protein adduct antibodies and the possible relationship with different hepatotoxic effects of the two compounds.

  1999cited by this paper
• Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist.

  1999cited by this paper
• Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac.

  1999cited by this paper
• Felbamate in Epilepsy Therapy

  1999cited by this paper
• [Fulminant hepatitis in two children treated with sulfasalazine for Crohn disease].

  1999cited by this paper
• Fatal Fulminant Hepatitis Associated with Bromfenac Use

  1999cited by this paper
• Bromfenac(Duract)-associated hepatic failure requiring liver transplantation

  1999cited by this paper
• Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications

  1999cited by this paper
• Interactions Between Anticonvulsant and Psychoactive Drugs

  1999cited by this paper
• Nefazodone-Induced Liver Failure: Report of Three Cases

  1999cited by this paper
• Acetaminophen hepatotoxicity: An update

  1999cited by this paper
• Hépatite fulminante chez deux enfants traités par la salazopyrine pour une maladie de Crohn

  1999cited by this paper
• Nefazodone-induced liver failure: report of three cases.

  1999cited by this paper
• Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation

  1999cited by this paper
• Felbamate

  1999cited by this paper
• [Acute hepatic necrosis in a patient treated with cyproterone acetate].

  1998cited by this paper
• A Mechanistic Approach to Antiepileptic Drug Interactions

  1998cited by this paper
• The role of oxygen free radicals in isoniazid-induced hepatotoxicity.

  1998cited by this paper
• Flutamide-induced acute hepatitis: investigation on the role of immunoallergic mechanisms.

  1998cited by this paper
• Effect of troglitazone on urinary excretion of 6beta-hydroxycortisol.

  1998cited by this paper
• Tacrine. A cause of fatal hepatotoxicity?

  1998cited by this paper
• Acute liver failure caused by isoniazid in a child receiving carbamazepine.

  1998cited by this paper
• Isolation and identification of bromfenac glucoside from rat bile.

  1998cited by this paper
• Environmental xenobiotics and the antihormones cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the CYP3A23 hormone response element.

  1998cited by this paper
• Clinical and toxicological consequences of the inductive potential of ethanol

  1998cited by this paper
• Potentially reactive cyclic carbamate metabolite of the antiepileptic drug felbamate produced by human liver tissue in vitro.

  1998cited by this paper
• Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.

  1997cited by this paper
• Pharmacokinetic Interactions with Felbamate

  1997cited by this paper
• Evaluation of Pharmacokinetic Interaction Between Bromfenac and Phenytoin in Healthy Males

  1997cited by this paper
• Characterization of the induction of rat microsomal cytochrome P450 by tacrine.

  1997cited by this paper
• Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)

  1997cited by this paper
• Genetic predisposition to drug-induced hepatotoxicity.

  1997cited by this paper
• Role of CYP2D6 in the N-hydroxylation of procainamide.

  1997cited by this paper
• Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: Evaluation of model drugs terfenadine and rifampin

  1997cited by this paper
• Immunotoxicology of the liver: adverse reactions to drugs.

  1997cited by this paper
• Quantitative reverse transcriptase/PCR assay for the measurement of induction in cultured hepatocytes.

  1997cited by this paper
• Cyclosporine and Nonsteroidal Antiinflammatory Drugs: Exploring Potential Drug Interactions and Their Implications for the Treatment of Rheumatoid Arthritis

  1997cited by this paper
• Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro.

  1997cited by this paper
• Inhibition of tacrine oral clearance by cimetidine

  1996cited by this paper
• The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity

  1996cited by this paper
• Steroidal drug cyproterone acetate is activated to DNA-binding metabolites by sulfonation.

  1996cited by this paper
• [Fulminant, rapidly reversible hepatitis and life-threatening anaphylaxis following rifampicin in an HIV-positive female patient with latent adrenal cortex insufficiency].

  1996cited by this paper
• Use of terfenadine and contraindicated drugs.

  1996cited by this paper
• The emerging role of cytochrome P450 3A in psychopharmacology.

  1995cited by this paper
• Hepatic Toxicity Associated with 2′-3'Dideoxyinosine in Children with AIDS

  1995cited by this paper
• Effects of the anticonvulsant, valproate, on the expression of components of the cytochrome-P-450-mediated monooxygenase system and glutathione S-transferases.

  1995cited by this paper
• Ebrotidine and its metabolites studied by mass spectrometry with electrospray ionization. Comparison of tandem and in-source fragmentation...

  1995cited by this paper
• Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans--a putative measure of CYP3A induction.

  1995cited by this paper
• [Acute hepatitis due to ingestion of Ecstasy].

  1995cited by this paper
• Biotransformation of sevoflurane.

  1995cited by this paper
• Inhibition of N‐Acetylation of Procainamide and Renal Clearance of N‐Acetylprocainamide by Para‐Aminobenzoic Acid in Humans

  1995cited by this paper
• Acute hepatitis due to ingestion of Ecstasy

  1995cited by this paper
• Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid

  1995cited by this paper
• Identification of 3 alpha-hydroxy-cyproterone acetate as a metabolite of cyproterone acetate in the bile of female rats and the potential of this and other already known or putative metabolites to form DNA adducts in vitro.

  1995cited by this paper
• Myeloperoxidase as a generator of drug free radicals.

  1995cited by this paper
• [Enalapril (Reniten)-associated toxic hepatitis].

  1994cited by this paper
• Determination of alpidem, an imidazopyridine anxiolytic, and its metabolites by column-switching high-performance liquid chromatography with fluorescence detection.

  1994cited by this paper
• [Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal].

  1994cited by this paper
• Hépatite imputable à l'alpidem (Ananxyl®) : quatre cas dont un mortel

  1994cited by this paper
• Hazards of ketoconazole therapy in testotoxicosis

  1994cited by this paper
• Toxicity of the antiandrogen flutamide in isolated rat hepatocytes.

  1994cited by this paper
• Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs.

  1994cited by this paper
• Acetaminophen hepatotoxicity: potentiation by isoniazid.

  1993cited by this paper
• Translational activation of ethanol-inducible cytochrome P450 (CYP2E1) by isoniazid.

  1993cited by this paper
• Effect of pyrazinamide on rifampicin kinetics in patients with tuberculosis.

  1993cited by this paper
• [Detection of antibody specific to rifampicin metabolite by ELISA--mechanism of sensitization by rifampicin].

  1993cited by this paper
• Comparative cytotoxicity of angiotensin-converting enzyme inhibitors in cultured rat hepatocytes.

  1993cited by this paper

• Tailored electrochemical sensing of phenolic pollutant via dysprosium molybdate-infused multi-walled carbon nanotubes for superior detection performance

  2025cites this paper
• Hydrothermal synthesis of MnCo2S4/CoS2 for the effective electrochemical detection of metol

  2025cites this paper
• Comparative in vitro hepatic clearances of commonly used antidepressants, antipsychotics, and anti-inflammatory agents in rainbow trout liver S9 fractions.

  2024cites this paper
• A developed Highly Selective and Sensitive Electrochemical Sensor using gold nanoparticles on Cerium Stannate/MXene as an Electrode Matrix for Detection of Metol in various Environmental and Biological Samples

  2024cites this paper
• Many human pharmaceuticals are weak inhibitors of the cytochrome P450 system in rainbow trout (Oncorhynchus mykiss) liver S9 fractions

  2024cites this paper
• Induction of CYP450 by illicit drugs: Studies using an in vitro 3D spheroidal model in comparison to animals.

  2022cites this paper
• Modeling drug-induced liver injury: current status and future prospects

  2022cites this paper
• Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury

  2022cites this paper
• In Silico Models for Hepatotoxicity.

  2022cites this paper
• Insight into the Practical Models for Prediciting the Essential Role of the Cytochrome P450-mediated Biotransformation in Emodin-associated Hepatotoxicity.

  2021cites this paper
• Drug‐Metabolizing Enzymes and Drug Toxicity

  2021cites this paper
• Drug‐Metabolism Enzymes and Transporter Activities as Risk Factors of Selected Marketed Drugs Associated with Drug‐Induced Fatalities

  2021cites this paper
• The Promise of AI for DILI Prediction

  2021cites this paper
• Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions

  2021cites this paper
• Transporter, Drug Metabolism, and Drug‐Induced Liver Injury in Marketed Drugs

  2021cites this paper
• Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice

  2021cites this paper
• Permeabilized Cryopreserved Human Hepatocytes as an Exogenous Metabolic System in a Novel Metabolism-Dependent Cytotoxicity Assay for the Evaluation of Metabolic Activation and Detoxification of Drugs Associated with Drug-Induced Liver Injuries: Results with Acetaminophen, Amiodarone, Cyclophosphami

  2021cites this paper
• Overview

  2021cites this paper
• Application of a fluorous derivatization method for characterization of glutathione-trapped reactive metabolites with liquid chromatography-tandem mass spectrometry analysis.

  2020cites this paper
• Drug‐Induced Liver Injury

  2020cites this paper
• What have we learned from animal models of idiosyncratic, drug-induced liver injury?

  2020cites this paper
• Prediction of seriniquinone-drug interactions by in vitro inhibition of human cytochrome P450 enzymes.

  2020cites this paper
• Models of Idiosyncratic Drug-Induced Liver Injury.

  2020cites this paper
• In silico prediction of drug-induced liver injury: Quo vadis?

  2019cites this paper
• Sequential drug delivery for liver diseases.

  2019cites this paper
• Evaluation of Drug-Induced Liver Injuries (DILI) with Human Hepatocytes: Scientific Rationale and Experimental Approaches

  2018cites this paper
• Overview of Mechanisms of Drug-Induced Liver Injury (DILI) and Key Challenges in DILI Research

  2018cites this paper
• Gender differences in pharmacological response : sex and adverse reactions

  2018cites this paper
• An integrative machine learning approach for prediction of toxicity-related drug safety

  2018cites this paper
• Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors

  2018cites this paper
• Evaluation of Strategies for the Assessment of Drug–Drug Interactions Involving Cytochrome P450 Enzymes

  2018cites this paper
• Identification of novel glutathione adducts of benzbromarone in human liver microsomes.

  2017cites this paper
• Evaluation of a human in vitro hepatocyte-NPC co-culture model for the prediction of idiosyncratic drug-induced liver injury: A pilot study

  2017cites this paper
• Idiosyncratic Drug-Induced Liver Injury: Is Drug-Cytokine Interaction the Linchpin?

  2017cites this paper
• Assessment of a Severity-Based Algorithm to Detect Signals of Severe Drug-Induced Liver Injury Using Spontaneous Reporting Database

  2017cites this paper
• A Comprehensive Review on Perfusion Cell Culture Systems

  2017cites this paper
• Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis

  2017cites this paper
• In Silico Models for Hepatotoxicity.

  2016cites this paper
• PROTECTIVE EFFECT OF ISONIAZID ON THIONAMIDE INDUCED IN MICE

  2016cites this paper
• Animal Models of Disease for Future Toxicity Predictions

  2016cites this paper
• Characterization of cytochrome P450 isoforms involved in sequential two-step bioactivation of diclofenac to reactive p-benzoquinone imines.

  2016cites this paper
• In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.

  2016cites this paper
• Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles.

  2016cites this paper
• Hepatotoxicity Induced by “the 3Ks”: Kava, Kratom and Khat

  2016cites this paper
• Editorial: Promising approaches to identify DILI drugs.

  2016cites this paper
• Practical approaches to resolving reactive metabolite liabilities in early discovery

  2015cites this paper
• The chemical, genetic and immunological basis of idiosyncratic drug–induced liver injury

  2015cites this paper
• Preventing Drug-Induced Liver Injury: How Useful Are Animal Models?

  2015cites this paper
• Evaluation of Adverse Drug Properties with Cryopreserved Human Hepatocytes and the Integrated Discrete Multiple Organ Co-culture (IdMOCTM) System

  2015cites this paper
• Hepatocyte-Based Metabolism, Drug–Drug Interaction, and Toxicity Assays in Drug Discovery and Drug Development to Minimize Attrition

  2015cites this paper
• Pharmacokinetic herb-drug interaction study of selected traditional medicines used as complementary and alternative medicine (CAM) for HIV/AIDS

  2015cites this paper
• Application of a discovery to targeted LC-MS proteomics approach to identify deregulated proteins associated with idiosyncratic liver toxicity in a rat model of LPS/diclofenac co-administration.

  2015cites this paper
• The Ascendancy of Second-Generation Antipsychotics as Frontline Antimanic Agents

  2015cites this paper
• High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes Are Two Important Predictors of Drug-Induced Liver Injury

  2014influential citation
• Liver damage associated with exposure to aspirin and diazinon in male rats and the ameliorative effect of selenium

  2014cites this paper
• Defining the Relationship between the Bioactivation of Lapatinib by CYP3A and Lapatinib-Induced Hepatotoxicity

  2014cites this paper
• Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury.

  2014cites this paper
• Biomarkers and human hepatocytes.

  2014cites this paper
• Predicting idiosyncratic drug-induced liver injury – some recent advances

  2014cites this paper
• Contribution of cytochrome P450 and UDT-glucuronosyltransferase to the metabolism of drugs containing carboxylic acid groups: risk assessment of acylglucuronides using human hepatocytes

  2014cites this paper
• In vitro human hepatocyte-based experimental systems for the evaluation of human drug metabolism, drug-drug interactions, and drug toxicity in drug development.

  2014cites this paper
• DMD056267 744..750

  2014influential citation
• SYSTEMIC COMPARISON OF DICLOFENAC INDUCED GENE EXPRESSION CHANGES IN DIVERSE IN VITRO AND IN VIVO MODELS AND SPECIES

  2014cites this paper
• Idiosyncratic drug-induced liver injury: an update on the 2007 overview

  2014cites this paper
• Bioactivation potential of thiophene-containing drugs.

  2014cites this paper
• Effects of Dietary Components on Acetaminophen-induced Liver Injury and Human Liver Cancer Cell Lines

  2014cites this paper
• Advanced in vitro models for studying drug induced toxicity

  2014cites this paper
• The role of glutathione in idiosyncratic and non-idiosyncratic drug induced liver injury

  2013cites this paper
• Role of drug-independent stress factors in liver injury associated with diclofenac intake.

  2013influential citation
• Hepatotoxicity: A scheme for generating chemical categories for read-across, structural alerts and insights into mechanism(s) of action

  2013cites this paper
• Utilization of Reverse Causal Reasoning of Hepatic Gene Expression in Rats to Identify Molecular Pathways of Idiosyncratic Drug-Induced Liver Injury

  2013cites this paper
• HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved

  2013cites this paper
• Glutathione-S-transferases: tools and targets for characterization of chemically reactive drug metabolites

  2013influential citation
• Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI).

  2013cites this paper
• Cytotoxic effects of benzbromarone and its 1'-hydroxy metabolite in human hepatocarcinoma FLC4 cells cultured on micro-space cell culture plates.

  2013cites this paper
• An in vitro tool to assess cytochrome P450 drug biotransformation-dependent cytotoxicity in engineered HepG2 cells generated by using adenoviral vectors.

  2013cites this paper
• glutathione adduct formation and daily dose

  2012cites this paper
• Role of Inflammation in Metabolism and Hepatotoxicity of Prototypical Drugs

  2012cites this paper
• Upgrading cytochrome P450 activity in HepG2 cells co-transfected with adenoviral vectors for drug hepatotoxicity assessment.

  2012cites this paper
• Endogenous interleukin-4 regulates glutathione synthesis following acetaminophen-induced liver injury in mice.

  2012cites this paper
• Gene expression profiling in primary rat hepatocytes for the prediction of hepatotoxicity

  2012cites this paper
• Identification and characterization of reactive metabolites in natural products-driven drug discovery.

  2012cites this paper
• In silico models for drug-induced liver injury – current status

  2012cites this paper
• Animal Models of Idiosyncratic, Drug-Induced Liver Injury: Emphasis on the Inflammatory Stress Hypothesis

  2012cites this paper
• Mechanism of exacerbative effect of progesterone on drug-induced liver injury.

  2012cites this paper
• Identification of CYP isozymes involved in benzbromarone metabolism in human liver microsomes

  2012cites this paper
• Toxicology and Adverse Drug Reactions

  2012cites this paper
• Biomarkers of Toxicity Panel in Clinical Trials

  2012cites this paper
• In vitro evaluation of the potential for drug-induced toxicity based on (35)S-labeled glutathione adduct formation and daily dose.

  2012cites this paper
• In silico prediction of adverse drug reactions and toxicities based on structural, biological and clinical data.

  2012cites this paper
• Liver Hypertrophy

  2012cites this paper
• Assessing the Hepatic Disposition and Toxicity of Xenobiotics Using Primary Hepatocytes

  2012cites this paper
• Idiosyncratic Drug Reactions

  2012cites this paper
• CYP2C9-Mediated Metabolic Activation of Losartan Detected by a Highly Sensitive Cell-Based Screening Assay

  2011cites this paper
• Animal models of idiosyncratic drug-induced liver injury—Current status

  2011cites this paper
• Review article: drug‐induced liver injury – its pathophysiology and evolving diagnostic tools

  2011cites this paper
• Ticlopidine-induced hepatotoxicity in a GSH-depleted rat model

  2011cites this paper
• Estradiol and progesterone modulate halothane-induced liver injury in mice.

  2011cites this paper
• Mixed learning algorithms and features ensemble in hepatotoxicity prediction

  2011cites this paper
• Conventional and novel approaches in generating and characterization of reactive intermediates from drugs/drug candidates.

  2011cites this paper